This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Lysine-specific demethylase 2 (KDM2); KDM7

In vitro and cell culture studies identified a hydroxamate-based inhibitor of KDM2 and KDM7 that could help treat cancer. In vitro and computational modeling studies identified a compound that inhibited KDM2 and KDM7 at low or submicromolar concentrations. In cancer cell lines, the compound decreased proliferation compared with no treatment. Next steps include testing the compound in xenograft mouse models of cancer.

SciBX 6(37); doi:10.1038/scibx.2013.1025
Published online Sept. 26, 2013

Patent application filed; available for licensing

Suzuki, T. et al. J. Med. Chem.; published online Aug. 21, 2013;
doi:10.1021/jm400624b
Contact: Naoki Miyata, Nagoya City University, Nagoya, Japan
e-mail:
miyata-n@phar.nagoya-cu.ac.jp
Contact: Tamio Mizukami, Nagahama Institute of Bio-Science and Technology, Shiga, Japan
e-mail:
mizukami@nagahama-i-bio.ac.jp
Contact: Takayoshi Suzuki,
Kyoto Prefectural University of Medicine, Kyoto, Japan
e-mail:
suzukit@koto.kpu-m.ac.jp